DIAMINE DERIVATIVES
PROBLEM TO BE SOLVED: To provide a new compound which has a strong activated blood coagulation factor X (hereinafter abbreviated as FXa)-inhibiting action and quickly exhibits a potent anticoagulant effect in oral administration. SOLUTION: A compound represented by formula (1) [wherein, R1and R2are...
Gespeichert in:
Hauptverfasser: | , , , , , , , , , , , , , |
---|---|
Format: | Patent |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | PROBLEM TO BE SOLVED: To provide a new compound which has a strong activated blood coagulation factor X (hereinafter abbreviated as FXa)-inhibiting action and quickly exhibits a potent anticoagulant effect in oral administration. SOLUTION: A compound represented by formula (1) [wherein, R1and R2are each hydrogen atom or the like; Q1is a saturated or unsaturated, 5-or 6-membered cyclic hydrocarbon group which may be substituted, or the like; Q2is a single bond or the like; Q3represents a group of formula (α) (wherein Q5is an alkylene group having 1 to 8 carbon atoms, or the like); and T0and T1are each carbonyl group or the like], a salt thereof, a solvate thereof, or an N-oxide thereof are provided. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, intravascular coagulation syndrome universalis, thrombus formation after artificial valve or joint replacement, thrombus formation and reocclusion after revascularization, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood withdrawal. COPYRIGHT: (C)2007,JPO&INPIT |
---|